

Monthly News – March 2013

Department of Psychiatry

March 18, 2013 Volume 7, Number 3

Events/Save the Date:

PTSD 2013: In Search of a New Paradigm

Featuring: Dr. Lenore Terr,
Dr. Sandro Galea and
Dr. Joseph Calabrese
Saturday, April 6, 2013

8:30 a.m. to 12 noon at the
Cleveland Racquet Club

For more information contact:
miriam.plax@uhhospitals.org

NAMI Greater Cleveland Annual Meeting: Thursday, April 18, 2013
at the Hilton Garden Inn in
downtown Cleveland.

Molly McVoy, M.D., will speak on
the DSM-V, the revised edition of
the Diagnostic & Statistical Manual
of Mental Disorders. For more
information or to register, contact
Kari Kepic at 216-875-7776 or via
email at: kkepic@namicleveland.org

Dr. Molly McVoy, Program
Training Director for the Child and
Adolescent Psychiatry Fellowship,
will be the guest speaker at the
Spring **Clinical Faculty Meeting**
on **Tuesday, April 30th**. Dr.
McVoy will speak on the DSM-V.

The Annual Meeting of the
**Cleveland Consultation- Liaison
Society** will take place on
**Wednesday, May 1, 2013 from
11:30 AM until 5:00 PM**, at the
Cleveland Skating Club. This
meeting is a great opportunity to
join with our psychiatric colleagues

from nearby communities. The
event begins with lunch followed by
presentations (both oral platform
presentations and posters).

Trainees and faculty members are
encouraged to submit abstracts
regarding their C/L research,
mystery cases, and innovative
programs. **The deadline for
abstract submission is April 3,
2013.** Abstract submissions will be
reviewed, and participants will be
notified of acceptance via email.

All attendees must register. The
meeting is pharma-free” again this
year! Faculty member attendees will
be asked to pay a \$50 fee at the
door on the day of the event (cash,
check, or credit card). Trainee
attendees will not be charged. **The
deadline for registration is April
10, 2013.**

To register online or for more
information:

<http://clevelandcls.webstarts.com>

Awards and Recognition:


Dr. Nora McNamara will receive
the Eugene Brudno Memorial
Provider Award for 2013 at the
NAMI Greater Cleveland Annual
Meeting on April 18th.

Cleveland Magazine Best Doctors
For 2013 included faculty members:
**Drs. Joseph Calabrese, Christina
Delos Reyes, Margaret Kotz,
Jeanne Lackamp, Joseph Locala,**


**Stephen Noffsinger, Phillip
Resnick, Robert Ronis, Stephen
Ruedrich, and Susan Stagno;**

Clinical faculty members honored:
as Best Doctors include: **Drs. Anna
Janicki, Stephen Levine, Kay
McKenzie and Mark Warren.**

**Drs. Narendra Singh and
Kathleen Svala** won the best
poster award for their presentation
“Smoking Cessation and Adolescent
Treatment Options”
at the All Ohio Institute on
Community Mental Health which
was held on March 1st and 2nd.



Posters were also presented by
PGY-3 resident, **Dr. Stephanie
Pope**, and former psychiatry
resident, **Dr. Pari Deshmukh.**



Comings and Goings:

Farewell to **Dr. Peter Corpus** who has accepted a position at Windsor-Laurelwood Center for Behavioral Medicine and will be leaving our department in March. **Dr. Corpus** has been the Medical Director of the Child and Adolescent Psychiatry Inpatient Unit since July of 2010.

Welcome to **Cheryl Findling, NP**, who joined the department on March 4th. She will be working on the Geriatric Psychiatry inpatient unit, in the community at nursing homes, and in the Walker building.

Congratulations:

To **Dr. Vincent Caringi** and his wife Rickie on the birth of their son, Domenico ("Nico") Loreto Caringi. Nico was born on March 15th, 6lbs 15oz and 19in long. Big sister Giada has clearly embraced her new role!



Congratulations to Addiction Psychiatry Fellow, **Narendra Singh, MD**, who has accepted a position at Memorial medical group and Memorial Health System in South Bend, Indiana beginning in July 2013.

Grand Rounds:

March 22nd:

Speaker: Pamelynn Esperanza, M.D. and Lysette Ramos, M.D.

Topic: The Life: Domestic Minor Sex Trafficking

March 29th:

Speaker: Blessing Igboeli, M.D.

Topic: Global Mental Health:

Lessons we can learn from Psychiatric Practices in St. Vincent's and The Grenadines

April 5th:

Speaker: Sandro Galea, M.D., Ph.D.

Topic: Psychiatric Epidemiology Beyond Cells and Societies: Implications and Complications

April 12th:

Speaker: Andrea Taylor, M.D.

Topic: A Look at Obesity and the Role of Mental Health

April 19th:

***Mayer Haber Lecture**

Speaker: Karoly Mirnics, M.D., Ph.D.

Topic: Neuroimmune Changes in Autism and Schizophrenia

April 26th:

***Willard D. Boaz Memorial Lecture**

Speaker: Jay Giedd, M.D.

Topic: TBA

- **Reception immediately following the lecture in the Mayer-Haber Conference Room 13-113**

New Clinical Service:

Dr. Chris Bedosky has implemented a new Anxiety and Obsessive Compulsive Disorders Intensive Treatment Program. The program provides adult, adolescent and child treatment for comorbid conditions and offers an Intensive Outpatient Program as well as treatment in a traditional outpatient setting. The main focus of the program is for individuals who are unable to attend school or work due to their disorder. There is a separate program for OCD patients. This program is self-pay only.

For more information, contact Dr. Bedosky at 216-983-0812 or via email at:

joseph.bedosky@uhhospitals.org

Presentations and Publications:

Dr. Martha Sajatovic presented at the following three meetings:

- "An update on a new treatment approach from homeless people with schizophrenia: Potential for improving outcomes in our local community." Presentation hosted by the Sisters of Charity Foundation, The Woodruff Foundation, and the Reuter Foundation. Trinity Commons, Cleveland, OH. February 14, 2013.

- "Physical Health and Medical Comorbidity in Older Adults with Bipolar Disorder." Symposium faculty presenter. American Association of Geriatric Psychiatry (AAGP) Annual meeting. Los Angeles, CA. March 2013.

- "Emerging Strategies to Enhance Engagement in Mental Health Care For Vulnerable Older Populations." Symposium faculty presenter. American Association of Geriatric Psychiatry (AAGP). Annual meeting. Los Angeles, CA. March 2013.

Wang, A.R., **Pagano, M. E., Scur, M. D., & Delos-Reyes, C. M.** (2013, April). Associations between anxiety disorders and substance use disorders in substance-dependent adolescents.

Poster presentation at the 43rd annual meeting of ASAM, Chicago, IL.

Delos Reyes, C. M., Svala, K., Singh, N., Scur, M., & Pagano, M. (2013, March). Smoking Cessation and Adolescent Treatment Outcomes. Poster presentation at the 11th All-Ohio Institute on Community Psychiatry, Beachwood, OH. First place research competition winner.

Research:

University Hospitals is now conducting a research study for children and adolescents between the ages of 7-17 with Generalized Anxiety Disorder or Major Depressive Disorder. Eligible participants may receive a thorough evaluation and study medication from a doctor who specializes in mental illness at no cost. To learn more, contact Becky Weintraub at 216-844-3922 or email at Becky.Weintraub@uhhsoptials.org.

OPT-BD Research Study

Do you see any patients who are **60 years old or older** with **type I Bipolar Disorder** and are currently **sub-optimally responsive** to their prescribed BD treatments?

To participate, individuals must:

- 1.) Have Type I Bipolar Disorder
- 2.) Be age 60 or older
- 3.) Have sub-optimal response to current psychotropic management including:
 - a. Behaviors and symptoms of irritability, agitation, mood lability or diminished ability to interact with others in their place of residence
 - b. Diminished ability to take care of basic personal needs in their place of residence due to symptoms of BD

To participate, individuals may NOT have:

- 1.) History of intolerance or resistance to asenapine
- 2.) Clinical diagnosis of dementia or Mini-mental state (MMSE) < 24
- 3.) History of TIA, stroke or MI within the past 12 months
- 4.) Rapid cycling BD defined as 4 or more discrete mood episodes within the previous 12 months.

Participants will receive 12 weeks of open-label asenapine. Each study subject will serve as their own baseline control and mood

symptoms will be assessed using standardized measures during the 12 weeks of asenapine therapy. The primary outcome is change from baseline in bipolar mood symptom scores (mania and depression). Secondary outcomes include functional and general health status, global psychopathology, side effects, and extrapyramidal symptoms.

For more information or to refer a patient contact Edna Fuentes-Casiano at 216-844-2104 or Effectiveness.Research@UHhospitals.org

CAE RCT Study

Do you have any patients who have Bipolar Disorder and have trouble taking all of their bipolar medication?

To participate, individuals must:

1. Have type I or type II bipolar disorder diagnosis for at least 2 years;
2. Have received treatment with at least one evidence-based medication to stabilize mood for at least six months (lithium, anticonvulsant, or antipsychotic mood stabilizer);
3. Be at least 20% or more non-adherent with current BD medication treatment (i.e. lithium, anticonvulsant, or antipsychotic mood stabilizer);
- 4.

To participate, individuals may NOT:

1. Be children under the age of 18

This is a randomized, controlled trial (RCT) of the **Customized Adherence Enhancement (CAE) psychosocial intervention** (created by Martha Sajatovic MD and Jennifer Levin PhD) vs. broadly-directed, non-individualized education (EDU) in **poorly adherent individuals with bipolar disorder (BD)**. The study is primarily interested in testing whether a (CAE) intervention that addresses the specific reasons for non-adherence among high-risk

patients with BD improves treatment adherence and bipolar disorder symptoms compared to EDU. CAE is intended to be a brief adjunct to standard mental health treatment. The proposed project has the potential to greatly advance the care of BD patients who are at greatest risk for poor health outcomes, with findings expected to be generalizable across a variety of treatment settings. *All individuals will continue to receive treatment as usual with their regular provider(s).*

For more information or to refer a patient contact Megan Brawley at 216-844-2835 or Effectiveness.Research@UHhospitals.org

Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Safety and Efficacy Study of Oral ELND005 as an Adjunctive Maintenance Treatment in Patients with Bipolar I Disorder

Principal Investigator: Keming Gao, MD, PhD

Gender & Age: Women & Men, ages 18 – 65

Diagnosis: Bipolar I Disorder, and has experienced a mood episode of any polarity within 4 months prior to the Screening Visit and responded to lamotrigine (LTG) or valproic acid (VPA).

Medications: Study subjects will be treated with ELND005 and weaned off of any other psychiatric medications they are taking during the open-label phase. Study patients who remain stable during this phase will be eligible for random assignment in the Double-blind Randomization Phase. In the double-blind phase, study patients will be randomly assigned in a 1:1 ratio to receive blinded treatment with either ELND005 or placebo for up to 48 weeks, in addition to either LTG or VPA

Study Details: Up to 72 weeks long

Contact: Carla Conroy/
216.844.2871/
Carla.Conroy@UHHospitals.org

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) 0.1, 0.4, and 0.8mg as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated with Bipolar 1 Disorder in Adult Subjects (TAK-375SL_201)

Principal Investigator: Keming Gao, MD, PhD

Gender & Age: Women & Men, ages 18 - 75

Diagnosis: Bipolar I Disorder, currently depressed

Medications: Lithium and/or one other mood stabilizer (lamotrigine or valproic acid) and/or one atypical antipsychotic (risperidone or olanzapine or aripiprazole or ziprasidone). Subjects may be on one, two or three medications but no more than one from each group. Each subject will be randomized to either TAK -375SL tablet 0.1 mg once daily, TAK-375SL tablet 0.4 mg once daily, TAK-375SL tablet 0.8 mg once daily or placebo once daily.

Study Details: Up to 13 weeks long, visits are once a week for the first month and then bi weekly for an additional month.

Contact: Carla Conroy/
216.844.2871/
Carla.Conroy@UHHospitals.org

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375SL 0.1, 0.4, and 0.8 mg as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar 1 Disorder in Adult Patients (TAK-375SL_203)

Principal Investigator: Keming Gao, MD, PhD

Gender & Age: Women & Men, ages 18 - 75

Diagnosis: Bipolar I Disorder, stable for at least eight weeks with a mood episode within 9 months from screening

Medications: Treatment as usual (antidepressants (except fluvoxamine), mood stabilizers and atypical antipsychotics). Each subject will be to either TAK - 375SL tablet 0.1 mg once daily, TAK-375SL tablet 0.4 mg once daily, TAK-375SL tablet 0.8 mg once daily or placebo once daily.

Study Details: Up to 11 months long, visits are every 2 weeks for the first 2 months and then monthly for an additional 6 months.

Contact: Carla Conroy/
216.844.2871/
Carla.Conroy@UHHospitals.org

Contact:

Published by University
Hospitals Dept. of Psychiatry
DEADLINE FOR NEXT ISSUE:
Friday, 04/12/2013

CONTACT: Kate Kilbane
Phone: 216-844-3658
kate.kilbane@uhhospitals.org

Correction: In the February newsletter Kasia Gustaw-Rothenberg was incorrectly referenced as a PGY-4 resident. Dr. Gustaw-Rothenberg is a PGY-3 Resident.